ArticleVaccines2022

Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2.

Matthew D Resch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.